Jasper Therapeutics Inc (JSPR) - Total Assets
Based on the latest financial reports, Jasper Therapeutics Inc (JSPR) holds total assets worth $21.18 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore JSPR debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Jasper Therapeutics Inc - Total Assets Trend (2019–2025)
This chart illustrates how Jasper Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See JSPR net assets for net asset value and shareholders' equity analysis.
Jasper Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Jasper Therapeutics Inc's total assets of $21.18 Million consist of 96.8% current assets and 3.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 80.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Jasper Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Jasper Therapeutics Inc (JSPR) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jasper Therapeutics Inc's current assets represent 96.8% of total assets in 2025, a decrease from 99.8% in 2019.
- Cash Position: Cash and equivalents constituted 80.2% of total assets in 2025, down from 99.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Jasper Therapeutics Inc Competitors by Total Assets
Key competitors of Jasper Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Jasper Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.26 | 4.31 | 1.96 |
| Quick Ratio | 2.26 | 4.31 | 1.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $11.30 Million | $40.84 Million | $8.82 Million |
Jasper Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Jasper Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.84 |
| Latest Market Cap to Assets Ratio | 0.36 |
| Asset Growth Rate (YoY) | -55.2% |
| Total Assets | $35.78 Million |
| Market Capitalization | $13.05 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jasper Therapeutics Inc's assets below their book value (0.36x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Jasper Therapeutics Inc's assets decreased by 55.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Jasper Therapeutics Inc (2019–2025)
The table below shows the annual total assets of Jasper Therapeutics Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $35.78 Million | -55.22% |
| 2024-12-31 | $79.90 Million | -15.80% |
| 2023-12-31 | $94.89 Million | +96.22% |
| 2022-12-31 | $48.36 Million | -48.36% |
| 2021-12-31 | $93.65 Million | +300.97% |
| 2020-12-31 | $23.36 Million | -14.16% |
| 2019-12-31 | $27.21 Million | -- |
About Jasper Therapeutics Inc
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commerci… Read more